Brokerages Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Price Target at $33.00

Avalo Therapeutics, Inc. (NASDAQ:AVTX) has been assigned a consensus rating of “Moderate Buy” from the ten research firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $33.00.

A number of brokerages recently weighed in on AVTX. Mizuho upgraded shares of Avalo Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Avalo Therapeutics in a research note on Friday, January 9th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of Avalo Therapeutics in a report on Thursday, January 15th. Finally, Guggenheim assumed coverage on shares of Avalo Therapeutics in a research note on Monday, February 2nd. They issued a “buy” rating and a $50.00 target price for the company.

Avalo Therapeutics Stock Down 2.3%

NASDAQ:AVTX opened at $16.71 on Tuesday. The firm has a market capitalization of $309.30 million, a price-to-earnings ratio of -3.12 and a beta of 0.84. Avalo Therapeutics has a twelve month low of $3.39 and a twelve month high of $20.72. The stock’s 50 day moving average price is $15.92 and its two-hundred day moving average price is $15.44.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Seven Fleet Capital Management LP acquired a new position in shares of Avalo Therapeutics during the 4th quarter worth approximately $1,150,000. XTX Topco Ltd lifted its holdings in Avalo Therapeutics by 190.0% during the 4th quarter. XTX Topco Ltd now owns 40,458 shares of the company’s stock valued at $735,000 after purchasing an additional 26,508 shares during the last quarter. Squadron Capital Management LLC bought a new position in Avalo Therapeutics during the fourth quarter worth $2,361,000. SummitTX Capital L.P. bought a new position in Avalo Therapeutics during the fourth quarter worth $3,557,000. Finally, Millennium Management LLC increased its holdings in shares of Avalo Therapeutics by 380.2% in the fourth quarter. Millennium Management LLC now owns 659,979 shares of the company’s stock valued at $11,985,000 after purchasing an additional 522,548 shares during the last quarter. 87.06% of the stock is currently owned by institutional investors.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.